Blab Tech
Butterfly Network Shares Surge 33% on Midjourney Medical Whole-Body Scanner Announcement
When Midjourney Medical unveiled a prototype whole‑body tomographic imaging machine, Butterfly Network’s stock leapt 33% in a single trading day, propelling the company to a new 52‑week high of $7.61 per share. The jump, which added $1.90 to the price, was driven by a volume of more than 16 million shares and reflected investor excitement about the new partnership.
The prototype—built around 40 Butterfly Ultrasound‑on‑Chip (UoC) modules—was announced today by Midjourney Medical. The device, licensed under a co‑development agreement between the two firms, promises to deliver high‑resolution imaging without the radiation or magnetic fields associated with conventional scanners. Butterfly’s CEO, Joseph De Vivo, highlighted the system’s strengths: “No radiation, no magnetic risk, low cost, and accessible – with about half a million sensors scanning simultaneously and over two petaflops of processing power.” He added that the scanner is designed for weekly use, offering a continuous window into a patient’s health.
Butterfly’s management confirmed that the collaboration is facilitated through its Butterfly Embedded business, formerly known as Octiv. The company filed the terms of the agreement in a Form 8‑K on November 17 2025, disclosing up to $74 million in expected payments to Butterfly over a five‑year term. A webinar scheduled for 12:00 pm EDT today will allow stakeholders to discuss the partnership in more detail.
The announcement arrives amid a broader surge in medical‑technology stocks. According to Investorideas.com, Butterfly’s shares were the top percentage gainer on the NYSE, while IceCure Medical Ltd. (NASDAQ: ICCM) topped the Nasdaq list the day before on its own news. The rally follows a 23% pre‑market jump reported by Yahoo Finance after Butterfly released strong Q4 results, including a 41% revenue increase to $31.5 million and a 55% rise in U.S. sales.
Butterfly’s UoC technology replaces traditional piezoelectric crystals with a single chip that contains thousands of capacitive micromachined ultrasonic transducers (CMUTs). The company has already commercialized the technology in its flagship Butterfly iQ3 device, a portable, single‑probe ultrasound system that has earned recognition from Prix Galien USA, Fierce 50, TIME’s Best Inventions, and Fast Company’s World Changing Ideas.
Industry analysts note that the medical‑devices market is expanding rapidly. Precedence Research projects global market size to grow from $678.88 billion in 2025 to nearly $1,209.42 billion by 2035, with a compound annual growth rate of 5.94% from 2026 to 2035.
The Midjourney Medical scanner is described as a full‑body tomographic imaging machine that uses 40 Butterfly UoC modules and is expected to evolve to use substantially more modules in future generations. The platform’s scalability is highlighted by the company’s statement that future iterations will “reflect the platform’s planned evolution and scalability.”
De Vivo also emphasized Butterfly’s commitment to democratizing personal imaging data. “We’re proud to support Midjourney’s mission to democratize access to personal imaging data,” he said. “The vision and roadmap Founder David Holz introduced yesterday also represents a potentially meaningful commercial opportunity for Butterfly.”
As of the latest trading session, Butterfly Network’s shares are trading at $7.61, up 33.19% from the previous close, with a 52‑week high of $8.01. The company will discuss the co‑development agreement in its upcoming webinar, and investors will be watching for further details on the scanner’s commercial launch timeline, regulatory approvals, and the full scope of the five‑year partnership.
In summary, Butterfly Network’s stock surge reflects investor enthusiasm for the company’s partnership with Midjourney Medical and the potential of its whole‑body scanner. The collaboration could bring significant revenue under the existing five‑year agreement, while the broader medical‑devices market continues to expand. Key questions remain about the scanner’s regulatory pathway, commercial rollout, and the extent of future module integration.
The prototype—built around 40 Butterfly Ultrasound‑on‑Chip (UoC) modules—was announced today by Midjourney Medical. The device, licensed under a co‑development agreement between the two firms, promises to deliver high‑resolution imaging without the radiation or magnetic fields associated with conventional scanners. Butterfly’s CEO, Joseph De Vivo, highlighted the system’s strengths: “No radiation, no magnetic risk, low cost, and accessible – with about half a million sensors scanning simultaneously and over two petaflops of processing power.” He added that the scanner is designed for weekly use, offering a continuous window into a patient’s health.
Butterfly’s management confirmed that the collaboration is facilitated through its Butterfly Embedded business, formerly known as Octiv. The company filed the terms of the agreement in a Form 8‑K on November 17 2025, disclosing up to $74 million in expected payments to Butterfly over a five‑year term. A webinar scheduled for 12:00 pm EDT today will allow stakeholders to discuss the partnership in more detail.
The announcement arrives amid a broader surge in medical‑technology stocks. According to Investorideas.com, Butterfly’s shares were the top percentage gainer on the NYSE, while IceCure Medical Ltd. (NASDAQ: ICCM) topped the Nasdaq list the day before on its own news. The rally follows a 23% pre‑market jump reported by Yahoo Finance after Butterfly released strong Q4 results, including a 41% revenue increase to $31.5 million and a 55% rise in U.S. sales.
Butterfly’s UoC technology replaces traditional piezoelectric crystals with a single chip that contains thousands of capacitive micromachined ultrasonic transducers (CMUTs). The company has already commercialized the technology in its flagship Butterfly iQ3 device, a portable, single‑probe ultrasound system that has earned recognition from Prix Galien USA, Fierce 50, TIME’s Best Inventions, and Fast Company’s World Changing Ideas.
Industry analysts note that the medical‑devices market is expanding rapidly. Precedence Research projects global market size to grow from $678.88 billion in 2025 to nearly $1,209.42 billion by 2035, with a compound annual growth rate of 5.94% from 2026 to 2035.
The Midjourney Medical scanner is described as a full‑body tomographic imaging machine that uses 40 Butterfly UoC modules and is expected to evolve to use substantially more modules in future generations. The platform’s scalability is highlighted by the company’s statement that future iterations will “reflect the platform’s planned evolution and scalability.”
De Vivo also emphasized Butterfly’s commitment to democratizing personal imaging data. “We’re proud to support Midjourney’s mission to democratize access to personal imaging data,” he said. “The vision and roadmap Founder David Holz introduced yesterday also represents a potentially meaningful commercial opportunity for Butterfly.”
As of the latest trading session, Butterfly Network’s shares are trading at $7.61, up 33.19% from the previous close, with a 52‑week high of $8.01. The company will discuss the co‑development agreement in its upcoming webinar, and investors will be watching for further details on the scanner’s commercial launch timeline, regulatory approvals, and the full scope of the five‑year partnership.
In summary, Butterfly Network’s stock surge reflects investor enthusiasm for the company’s partnership with Midjourney Medical and the potential of its whole‑body scanner. The collaboration could bring significant revenue under the existing five‑year agreement, while the broader medical‑devices market continues to expand. Key questions remain about the scanner’s regulatory pathway, commercial rollout, and the extent of future module integration.
